27920091|t|Interferon-γ Limits Diabetogenic CD8(+) T-Cell Effector Responses in Type 1 Diabetes
27920091|a|Type 1 diabetes development in the NOD mouse model is widely reported to be dependent on high - level production by autoreactive CD4(+) and CD8(+) T cells of interferon-γ (IFN-γ), generally considered a proinflammatory cytokine. However, IFN-γ can also participate in tolerance-induction pathways, indicating it is not solely proinflammatory. This study addresses how IFN-γ can suppress activation of diabetogenic CD8(+) T cells. CD8(+) T cells transgenically expressing the diabetogenic AI4 T-cell receptor adoptively transferred disease to otherwise unmanipulated NOD. IFN-γ (null), but not standard NOD, mice. AI4 T cells only underwent vigorous intrasplenic proliferation in NOD. IFN-γ (null) recipients. Disease -protective IFN-γ could be derived from any lymphocyte source and suppressed diabetogenic CD8(+) T-cell responses both directly and through an intermediary nonlymphoid cell population. Suppression was not dependent on regulatory T cells, but was associated with increased inhibitory STAT1 to STAT4 expression levels in pathogenic AI4 T cells. Importantly, IFN-γ exposure during activation reduced the cytotoxicity of human-origin type 1 diabetes - relevant autoreactive CD8(+) T cells. Collectively, these results indicate that rather than marking the most proinflammatory lymphocytes in diabetes development, IFN-γ production could represent an attempted limitation of pathogenic CD8(+) T-cell activation. Thus, great care should be taken when designing possible diabetic intervention approaches modulating IFN-γ production.
27920091	0	12	Interferon-γ	T116,T121,T129	C3539881
27920091	13	19	Limits	T169	C0439801
27920091	20	55	Diabetogenic CD8(+) T-Cell Effector	T025	C0242629
27920091	69	84	Type 1 Diabetes	T047	C0011854
27920091	85	100	Type 1 diabetes	T047	C0011854
27920091	101	112	development	T169	C1527148
27920091	120	135	NOD mouse model	T050	C2986594
27920091	161	170	dependent	T080	C1701901
27920091	174	178	high	T080	C0205250
27920091	181	186	level	T080	C0441889
27920091	187	197	production	T169	C0205245
27920091	201	213	autoreactive	T080	C0205332
27920091	214	220	CD4(+)	T025	C0039215
27920091	225	239	CD8(+) T cells	T025	C0242629
27920091	243	255	interferon-γ	T116,T121,T129	C3539881
27920091	257	262	IFN-γ	T116,T121,T129	C3539881
27920091	275	285	considered	T078	C0750591
27920091	288	303	proinflammatory	T169	C0333348
27920091	304	312	cytokine	T116,T129	C0079189
27920091	323	328	IFN-γ	T116,T121,T129	C3539881
27920091	338	349	participate	T169	C0679823
27920091	353	372	tolerance-induction	T038	C1817959
27920091	373	381	pathways	T044	C1704259
27920091	383	393	indicating	T078	C3146298
27920091	400	403	not	T169	C1518422
27920091	404	410	solely	T081	C0205171
27920091	411	426	proinflammatory	T169	C0333348
27920091	453	458	IFN-γ	T116,T121,T129	C3539881
27920091	463	471	suppress	T169	C1260953
27920091	472	482	activation	T043	C1326120
27920091	486	513	diabetogenic CD8(+) T cells	T025	C0242629
27920091	515	529	CD8(+) T cells	T025	C0242629
27920091	530	555	transgenically expressing	T045	C1171362
27920091	560	572	diabetogenic	T047	C0011847
27920091	573	576	AI4	T047	C1863012
27920091	577	592	T-cell receptor	T116,T129,T192	C0034790
27920091	604	615	transferred	T080	C0332261
27920091	616	623	disease	T047	C0012634
27920091	637	654	unmanipulated NOD	T015	C0085243
27920091	656	661	IFN-γ	T116,T121,T129	C3539881
27920091	687	696	NOD, mice	T015	C0085243
27920091	698	701	AI4	T047	C1863012
27920091	702	709	T cells	T025	C0039194
27920091	734	746	intrasplenic	T082	C1254362
27920091	747	760	proliferation	T043	C0596290
27920091	764	767	NOD	T015	C0085243
27920091	769	774	IFN-γ	T116,T121,T129	C3539881
27920091	776	780	null	T169	C0332197
27920091	794	801	Disease	T047	C0012634
27920091	814	819	IFN-γ	T116,T121,T129	C3539881
27920091	829	836	derived	T080	C1441547
27920091	846	856	lymphocyte	T025	C0024264
27920091	868	878	suppressed	T169	C1260953
27920091	879	905	diabetogenic CD8(+) T-cell	T025	C0242629
27920091	906	915	responses	T043	C0007613
27920091	958	969	nonlymphoid	T024	C0040300
27920091	970	985	cell population	T025	C0007634
27920091	1031	1038	T cells	T025	C0039194
27920091	1048	1063	associated with	T080	C0332281
27920091	1064	1073	increased	T081	C0205217
27920091	1074	1084	inhibitory	T052	C3463820
27920091	1085	1090	STAT1	T116,T123	C0287920
27920091	1094	1099	STAT4	T116,T123	C0255034
27920091	1100	1110	expression	T045	C1171362
27920091	1111	1117	levels	T080	C0441889
27920091	1121	1131	pathogenic	T169	C0543483
27920091	1132	1135	AI4	T047	C1863012
27920091	1136	1143	T cells	T025	C0039194
27920091	1158	1163	IFN-γ	T116,T121,T129	C3539881
27920091	1173	1179	during	T079	C0347984
27920091	1180	1190	activation	T043	C1326120
27920091	1191	1198	reduced	T080	C0392756
27920091	1203	1215	cytotoxicity	T049	C0596402
27920091	1219	1231	human-origin	T077	C4287933
27920091	1232	1247	type 1 diabetes	T047	C0011854
27920091	1250	1258	relevant	T080	C2347946
27920091	1259	1271	autoreactive	T080	C0205332
27920091	1272	1286	CD8(+) T cells	T025	C0242629
27920091	1308	1315	results	T169	C1274040
27920091	1316	1324	indicate	T078	C3146298
27920091	1359	1374	proinflammatory	T169	C0333348
27920091	1375	1386	lymphocytes	T025	C0024264
27920091	1390	1398	diabetes	T047	C0011847
27920091	1399	1410	development	T169	C1527148
27920091	1412	1417	IFN-γ	T116,T121,T129	C3539881
27920091	1418	1428	production	T169	C0205245
27920091	1435	1444	represent	T052	C1882932
27920091	1458	1468	limitation	T169	C0449295
27920091	1472	1482	pathogenic	T169	C0543483
27920091	1483	1496	CD8(+) T-cell	T025	C0242629
27920091	1497	1507	activation	T043	C1326120
27920091	1515	1520	great	T081	C1704243
27920091	1521	1525	care	T061	C0150544
27920091	1547	1556	designing	T052	C1707689
27920091	1566	1574	diabetic	T047	C0011847
27920091	1575	1587	intervention	T061	C0184661
27920091	1588	1598	approaches	T082	C0449445
27920091	1599	1609	modulating	T082	C0443264
27920091	1610	1615	IFN-γ	T116,T121,T129	C3539881
27920091	1616	1626	production	T169	C0205245